TiumBio님의 업데이트

We are excited to announce that we dosed our first patient in Phase 2 clinical trial of oral immuno-oncology drug TU2218! The Phase 2a trial of TU2218 starts with head and neck squamous cell carcinoma, as well as biliary tract cancer patients. It will be later expanded to colorectal cancer patients. Read more : https://lnkd.in/gMwCxHmA

We are encouraged to see early results from clinical trials of TU2218, a dual inhibitor targeting both TGF-beta and VEGF for the treatment of solid tumors, with anti-PD-1 antibody. Check out this interview at the European Society for Medical Oncology (ESMO) 2024 Congress. https://lnkd.in/gT7YraFK #TiumBio #ESMO2024 #Oncology

👨⚕️ Tiumbio is Hiring!! 👩⚕️ #티움바이오 에서 치료용 #항체개발 연구 포지션의 인재를 채용하고 있습니다. 희귀질환 치료제 개발을 위한 #항체개발 연구에 전문성을 갖고 계시는 분이라면 누구나 환영입니다! 치료용 항체 개발 연구 - 항체 및 단백질 치료제 개발 실무 연구(활성평가, 특성분석, 엔지니어링 등) - 개발 현황 파악 및 관련 분석법 세팅/평가 지원자격 - 생물학, 분자생물학, 생명 공학 석사 이상 학위 소지자 - 대리~차장급 경력 우대사항 - 박사 학위자 - 라이브러리를 이용한 치료제 개발 경험자- 항체 연구 업무 5년 - 회사 내 항체 및 단백질 치료제 개발 연구 경험 3~5년 이상 #티움바이오 #바이오 #바이오신약 #항체개발 #희귀질환치료제 #면역항암제 #제약바오 #치료용항체개발 #제약바이오 #항체엔지니어링 #Phagelibrary #항체발굴 #신규분석법 #항체활성평가 #항체특성분석 #항체최적화 😁 자세한 내용은 아래 채용 공고를 참고 해 주세요. 😀 https://lnkd.in/eyR5ADA6

👨⚕️ Tiumbio is Hiring!! 👩⚕️ #티움바이오 에서 #임상PM 포지션을 채용하고 있다는 사실 알고 계신가요?? 희귀질환 치료제 개발을 위한 #Global임상 에 전문성을 갖고 계시는 분이라면 누구나 환영입니다! 임상 PM (Project Management) - 임상 (국내/해외) 기획, 운영 및 관리 - Project set-up/management - Clinical development/strategy 수립 - Budget/timeline 관리 - CRO등 vendor 관리 - 임상시험용의약품 관련 vendor 관리 지원자격 - 약학, 생명공학/과학, 간호학 등 관련 전공 학사 이상 - 제약·바이오기업 PM 경력 - 영어 Communication skill보유 우대사항 - 약학, 생명공학/과학, 간호학 등 관련 전공 석·박사  - 해외 (미국, 유럽 등) 임상시험 운영 유경험자 자세한 내용은 아래 채용 공고를 참고 해 주세요. https://lnkd.in/eyR5ADA6 #티움바이오 #임상 #임상PM #글로벌임상 #신약개발 #희귀질환치료제 #면역항암제 #제약바이오 #CRA #CRO #Biotech #Tiumbio #ClinicalReasearch

TiumBio plans to initiate a Phase 1b clinical trial of #TU7710, a long-acting recombinant activated factor VII, in patients with #hemophilia in Europe. Read more at https://lnkd.in/ggi24Trc

We are thrilled to announce that TiumBio's hemophilia treatment candidate has shown promising clinical data from a Phase 1 trial. The company presented interim study results at the 32nd Congress of the International Society on Thrombosis and Haemostasis. #hemophilia #orphan #TiumBio #ISTH #extended - Poster: https://lnkd.in/dNZSrBti - Press release: https://lnkd.in/d_S2YvPt

TiumBio will present interim results from an ongoing Phase 1a clinical trial of TU7710, a novel recombinant fusion protein linking activated FVII with human transferrin, indicated for the treatment of hemophilia patients with inhibitors, at the International Society on Thrombosis and Haemostasis (ISTH) Annual Congress on Monday, June 24, 2024, at 1:45 pm ICT. #Heamophilia #TU7710 #TiumBio #inhibitors #prolonged #study Find more: https://lnkd.in/gZ2qj9mT

TiumBio presented interim results from an ongoing Phase 1b clinical trial of TU2218 in combination with pembrolizumab in patients with advanced solid tumors at the ASCO 2024 Annual Meeting. "We are encouraged by the preliminary efficacy results with a favorable safety profile in patients with advanced tumors and are looking forward to top-line data from the study, which is expected in the second half of this year," said Hun-Taek Kim, Ph.D., MBA, CEO at TiumBio. Read more: https://lnkd.in/ghxfTXp5

"We are thrilled that merigolix, a once-daily oral gonadotropin hormone-releasing hormone receptor antagonist, demonstrated clinically meaningful and statistically significant reductions in dysmenorrhea in its Phase 2a clinical trial for endometriosis. We are confident that this new molecule will be best-in-class not only for endometriosis but also for uterine fibroids." - Hun-Taek Kim, Ph.D., MBA, CEO of TiumBio #merigolix #endometiosis #women's health https://lnkd.in/gAgZcQk8